Pfizer Expands Anti-Infective Portfolio With $1.9 Bil. Vicuron Acquisition

Vicuron's near-term candidates include the antibiotic dalbavancin, which has a Sept 21 user fee deadline, and the antifungal anidulafungin, also pending at FDA. Pfizer's acquisition of Vicuron is expected to close in the third quarter.